GlassScriptPhysician profile
Janette Grigg
NPI 1326305418
$3,361.70
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,527 · 2022: $711 · 2023: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $452.28 | 2021 | |
| Abbvie INC. | $380.62 | 2021-2023 | |
| Ucb, INC. | $181.37 | 2021 | |
| Kyowa Kirin, INC. | $158.21 | 2021 | |
| Edwards Lifesciences Corporation | $157.30 | 2021 | |
| Biogen, INC. | $139.49 | 2021 | |
| Lundbeck LLC | $124.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $124.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.82 | 2022 | |
| Myovant Sciences INC. | $121.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.57 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $109.93 | 2022 | |
| Novo Nordisk INC | $98.21 | 2022 | |
| Scynexis, INC. | $83.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.98 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $80.08 | 2021 | |
| Sk Life Science, INC. | $78.46 | 2021 | |
| Neurocrine Biosciences, INC. | $73.26 | 2021 | |
| Sunovion Pharmaceuticals INC. | $64.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.70 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $62.19 | 2021 | |
| Adamas Pharmaceuticals, INC. | $61.70 | 2021 | |
| Amneal Pharmaceuticals LLC | $59.47 | 2021 | |
| Almatica Pharma LLC | $54.09 | 2021 | |
| Eisai INC. | $49.30 | 2021 | |
| Acorda Therapeutics, INC | $49.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $45.89 | 2021 | |
| Greenwich Biosciences, INC. | $34.47 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $31.87 | 2021 | |
| Neurelis, INC. | $30.03 | 2021 | |
| Amgen INC. | $26.80 | 2021 | |
| Genzyme Corporation | $22.68 | 2021 | |
| Terumo Bct, INC. | $17.98 | 2021 | |
| Aquestive Therapeutics, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janette Grigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.